News

INmune Bio Inc. to Present at Key Healthcare Conference

INmune Bio Inc. to Present at Key Healthcare Conference

INmune Bio Inc. at the RBC Capital Markets Global Healthcare Conference

INmune Bio Inc. (NASDAQ: INMB), a pioneering clinical-stage biotechnology firm based in Boca Raton, Florida, is set to showcase its innovative research at the upcoming RBC Capital Markets Global Healthcare Conference. This noteworthy event will take place on May 20-21, where the company will reveal its cutting-edge advancements in the fields of inflammation and immunology.

Event Details

The RBC Capital Markets Global Healthcare Conference offers the ideal platform for INmune Bio to engage with investors and stakeholders. The event will follow a unique format, including a Fireside Chat and one-on-one virtual meetings. Attendees can find INmune Bio's presentation scheduled for 11:00 am EDT. Such conferences are crucial as they facilitate valuable connections and provide insights into the company's strategic direction and scientific breakthroughs.

About INmune Bio Inc.

Founded with the vision of transforming how diseases linked to the innate immune system are treated, INmune Bio is at the forefront of biotechnology innovation. The company has developed three primary product platforms that leverage dominant-negative technologies aimed at neutralizing key inflammatory factors.

The Dominant-Negative Platform

At the heart of INmune Bio’s offerings is the Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform. This innovative technology focuses on selectively neutralizing soluble tumor necrosis factor, which is often a significant contributor to innate immune dysfunction and underlies many chronic diseases. Clinical trials involving DN-TNF candidates are currently investigating potential treatments for mild Alzheimer’s disease, mild cognitive impairment, and treatment-resistant depression, branded as XPro™.

Natural Killer Cell Priming

Additionally, the Natural Killer Cell Priming Platform is an exciting initiative that includes INKmune®. Designed to activate a patient’s natural killer (NK) cells, INKmune® aims to eradicate minimal residual disease in cancer patients. Current trials are examining its efficacy in treating metastatic castration-resistant prostate cancer, an area that desperately needs new therapeutic approaches.

Cord-Strom Cell Technology

Another promising avenue for INmune Bio is its proprietary CORDStrom™ program, which utilizes human umbilical cord-derived mesenchymal stem/stromal cells (hucMSCs). Recently, this program concluded a blinded randomized trial for recessive dystrophic epidermolysis bullosa, demonstrating the company’s commitment to addressing various medical challenges through advanced biotechnology.

Commitment to Innovation

As a publicly traded entity, INmune Bio Inc. is dedicated to pushing the boundaries of medical science. By focusing on a precision medicine approach, it addresses diseases that are largely driven by chronic inflammation and offers hope for better patient outcomes. Interested parties are encouraged to learn more about their pioneering work and product platforms by visiting their official website.

Frequently Asked Questions

What is the purpose of INmune Bio's presentation at the conference?

INmune Bio aims to showcase its innovations in biotechnology focused on inflammation and immunology, providing insights into their ongoing research and development.

When will the RBC Capital Markets Global Healthcare Conference occur?

The conference is scheduled for May 20-21, where INmune Bio will participate in key discussions and presentations relevant to their field.

What technologies does INmune Bio focus on?

INmune Bio focuses on several innovative platforms, including DN-TNF for inflammatory diseases, NK cell priming for cancer, and CORDStrom™ for regenerative medicine.

How can I learn more about INmune Bio?

You can explore more about INmune Bio and their product platforms by visiting their website at www.inmunebio.com.

What is the significance of the company's research?

INmune Bio's research is crucial as it explores novel therapies for conditions usually linked with chronic inflammation, providing potential new solutions for complex diseases.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Ascletis Kicks Off Phase III Trials for Oral GLP-1 Drug

Updated Category News Views 33

Dose One: A Step Closer to an Oral Obesity Treatment August 30, 2026, marks a pivotal moment for Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") as they announce the first patient dosed in their global phase III clinical trial of ASC30. This little pill might pack a punch, tackling obesity—a beast of a challenge that's battering waistlines globally. So what's the big deal...

Continue Reading
ONEOK's Strategic Move: Acquiring Brazos Assets

Updated Category News Views 15

ONEOK's Bold Acquisition Move ONEOK Inc., a heavyweight in the energy sector, is making headlines yet again. This time, they are shelling out a whopping $4.425 billion in cash for Brazos Midstream's prized assets over in the Permian Midland Basin. The game plan? Expand their energy infrastructure without issuing new equity to diminish their leverage. It's a gutsy maneuver...

Continue Reading
Lesotho Unveils Digital Registry for Farmers Nationwide

Updated Category News Views 29

Game-Changer for Lesotho's Agriculture Alright, time to talk about something that's a real shot in the arm for farmers over in Lesotho. The Ministry of Agriculture, Food Security and Nutrition (MAFSN) has launched the Lesotho Farmers Portal. This isn't just another fancy software tool; it's a digital revolution aimed to tip the scales in favor of the folks getting their...

Continue Reading
PG&E Critiques Senate Bill 492's Wildfire Solutions

Updated Category News Views 14

PG&E's Take on Senate Bill 492: More to Be Desired Sit down for a moment, because PG&E's not mincing words with their latest statement. Talking about Senate Bill 492, PG&E puts it plain and clear—this legislation is just skirting around the edges of what's really needed to tackle California's wildfire crisis. In their eyes, it's like putting a band-aid on a wound that...

Continue Reading
Caleb Hudson Claims Bassmaster Rookie of the Year Title

Updated Category News Views 1

A Rookie Year Like No Other Ever felt like the universe is testing your nerves by dangling victory just out of reach? Caleb Hudson, a young bass angler from Georgia, knows that feeling all too well. On the surface, his journey through the 2026 Pro-Guide Batteries Elite Series seemed a runaway success. But on the last day of the season, while his main rival was casting...

Continue Reading
DRAGON BALL GEKISHIN SQUADRA: Big Overhaul as Year Two Begins

Updated Category News Views 43

Games Get Old Fast — Unless You Keep them Fresh From the folks at Bandai Namco Entertainment Inc, there's big news about DRAGON BALL GEKISHIN SQUADRA as it celebrates its first anniversary. The game is looking toward a bright future with a Year-End Overhaul and a new season launch on September 9. If you're a fan of explosive animations and team-based chaos, you'll want...

Continue Reading
Lozano Triumphs in Cycling Classic's Rugged Terrain

Updated Category News Views 6

Defying All Odds in Philadelphia David Lozano, a spirited Spaniard who doesn't let a little thing like type 1 diabetes slow him down, just snagged the King of the Mountains title at the Philadelphia Cycling Classic. This wasn't just about crossing the finish line in a major race after a decade-long hiatus; it was a showcase of raw grit, determination, and a little bit of...

Continue Reading
WuXi AppTec Boosts Dividend Again, Hits RMB 1.51B

Updated Category News Views 4

Dividend Hike: A Sign of Resilience Well, if there's one thing that always perks up the ears of investors, it's a substantial bump in dividends. WuXi AppTec, a heavyweight in the pharmaceutical CRDMO sector, has significantly raised its 2026 interim cash dividend to a cool RMB 1.51 billion. And for those keeping score, that's up from RMB 1.03 billion last year. This isn't...

Continue Reading
DoGo Power's Bold Move: AI and Grid-Forming Energy

Updated Category News Views 5

Pioneering Change in Energy Storage The times are a-changin', and DoGo Power seems determined to ride the wave. At Intersolar South America 2026 in São Paulo, DoGo put the pedal to the metal, showcasing their latest foray into AI and grid-forming energy storage technology. Now, if you're wondering whether this is just another flash in the tech pan or if it's some real...

Continue Reading
Chinese NEV Giants Redefine the Auto Industry

Updated Category News Views 41

China's Auto Game Changers: Numbers Don't Lie Alright, let's cut straight to the chase here. You can't ignore those numbers if you tried—40.3% to 77.4% in three short years. We're talking about the flip in the domestic market share for Chinese-brand passenger cars, from 2023 to mid-2026. That's a massive leap for any industry, let alone the auto sector, which is slower...

Continue Reading

Top 5 Most Recently Viewed Articles

Carmila Set to Release Significant Financial Insights Soon

Updated Category News Views 204

Carmila's Upcoming Financial Results Announcement Carmila, a prominent name in commercial real estate, is gearing up to unveil its full-year results for 2024. This significant event is scheduled for a Tuesday afternoon, with results expected to be published after the market closes. The presentation following the results will occur the next morning, offering investors...

Continue Reading
Sana Biotechnology Shareholders Urged to Act Before Deadline

Updated Category News Views 138

Investors Alert: Opportunities for Sana Biotechnology, Inc. The Gross Law Firm is reaching out to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA) to inform them about an important class action lawsuit. Many shareholders are encouraged to take prompt action to safeguard their investments. Understanding the Class Action Lawsuit The lawsuit focuses on those who...

Continue Reading
VacationOffer.com Brings Exciting Travel Opportunities Nationwide

Updated Category News Views 152

VacationOffer.com Showcases Exclusive Travel Deals Across Events VacationOffer.com is hitting the road to bring its remarkable travel deals directly to consumers at major trade shows, bridal expos, sporting events, and various shopping venues nationwide. With the goal of transforming affordable travel into a reality for many, the company is thrilled to connect personally...

Continue Reading
Great Elm Capital Corp. Shares Insights on First Brands Loans

Updated Category News Views 220

Great Elm Capital Corp. Provides Insights on First Brands Investments In a recent announcement, Great Elm Capital Corp. (NASDAQ: GECC) addressed important queries from investors regarding its financial involvement with First Brands Group, LLC, a prominent name in the global automotive parts sector. This communication comes at a critical time as First Brands has recently...

Continue Reading
Darren Roman Enhances Finance Team at Dorsey in Phoenix

Updated Category News Views 163

So, Darren Roman joined Dorsey & Whitney's Phoenix office as Of Counsel in their Finance & Restructuring group. Back when that announcement hit, folks were buzzing—he brought a hefty resume full of complex transaction know-how. You know the type, right? The ones who can navigate through the financial jungle without losing a limb. Traders eyed this with interest; having...

Continue Reading